300 filings
Page 3 of 15
8-K
fk4je7sfmpuik
20 Dec 22
Oragenics, Inc. Receives NYSE American Notice
4:55pm
8-K
o89 a3p7a3p0k
19 Dec 22
Oragenics, Inc. Announces New Chair
4:51pm
8-K
i5vnd nwdfa3t
16 Dec 22
Departure of Directors or Certain Officers
4:05pm
8-K
gcmt51rdrjt4ztp6ti
16 Nov 22
Departure of Directors or Certain Officers
4:15pm
8-K
tavj8y2vbnonxwb n7oe
3 Oct 22
Regulation FD Disclosure
9:15am
8-K
4uhwmnexgn4exfq
30 Sep 22
Oragenics Issues Letter to Shareholders
9:00am
8-K
1lo762m r6ey3sd
24 Aug 22
Oragenics Announces Favorable Preliminary Toxicology Data for Intranasal COVID-19 Vaccine Candidate
8:02am
8-K
ngb1ch
3 Aug 22
Departure of Directors or Certain Officers
4:05pm
8-K
54xk32fl g7
8 Jul 22
Departure of Directors or Certain Officers
4:04pm
8-K
pgr89wjl0u45cmg
23 Jun 22
Oragenics Appoints Seasoned Vaccine Executive Kimberly Murphy as President and Chief Executive Officer
5:22pm
8-K
icgcyh8soin2ah mj8x
17 May 22
Oragenics Issues Letter to Shareholders
9:30am
8-K
co2z4p3r
19 Apr 22
Regulation FD Disclosure
5:14pm
8-K
1c1q6zsucz
6 Apr 22
Oragenics Extends Collaboration to Develop Vaccines against Future Variants of Coronaviruses
7:45am
8-K
g7vk6ly
10 Mar 22
Oragenics Engages KBI Biopharma to Support Development of Intranasal COVID-19 Vaccine Candidate NT-CoV2-1
7:47am
8-K
4r2gya
28 Feb 22
Material Modifications to Rights of Security Holders
12:00am
8-K
31jun
26 Jan 22
Oragenics Announces Adjournment of Annual Meeting of Shareholders
9:04am
8-K
fst en57ned
20 Dec 21
Oragenics Extends Collaboration with the National Research Council of Canada to Develop
8:19am
8-K
lofp0dtsvo910h
20 Dec 21
Departure of Directors or Certain Officers
12:00am
8-K
g3t01
14 Dec 21
Regulation FD Disclosure
4:05pm
8-K
cfhqn2t0qnf 9a
1 Dec 21
Oragenics Announces Positive COVID-19 Challenge Study Results Evaluating Multiple Formulations of its SARS-CoV-2 Vaccine Candidate
9:02am